A Phase II/III Randomized Trial of Two Doses of MK-3475 (SCH900475) versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer

Diseases and Conditions Researched


What is the purpose of this trial?

This study will compare two doses of MK-3475 versus docetaxel in participants with non-small cell lung cancer (NSCLC) who have experienced disease progression after platinum-containing systemic therapy. Participants will be assigned randomly to receive either Low Dose or High Dose MK-3475 every three weeks (Q3W), or docetaxel at 75 mg/m^2 Q3W. This study will use an adaptive trial design so that the total number of participants randomized will depend upon demonstration of sufficient objective responses at interim analysis. If the MK-3475 Low Dose arm is closed, participants may receive MK-3475 High Dose therapy.

Participation Guidelines

Age: Any
Gender: Both

Click here for detailed participation information for this trial.

Sponsor: Merck Sharp & Dohme
Last Updated:
Study HIC#: 1307012448